Grifols, S.A. (NASDAQ:GRFS - Get Free Report) declared a -- dividend on Thursday, July 31st, Wall Street Journal reports. Investors of record on Tuesday, August 12th will be given a dividend of 0.1404 per share by the biotechnology company on Wednesday, August 20th. The ex-dividend date of this dividend is Tuesday, August 12th.
Grifols Stock Performance
Shares of GRFS traded down $0.15 during midday trading on Thursday, reaching $10.70. The stock had a trading volume of 838,798 shares, compared to its average volume of 970,602. The firm has a 50 day simple moving average of $9.09 and a 200-day simple moving average of $7.98. Grifols has a one year low of $6.19 and a one year high of $11.14. The firm has a market cap of $7.36 billion, a PE ratio of 9.15, a P/E/G ratio of 0.39 and a beta of 0.55. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in shares of Grifols in the 2nd quarter worth about $95,000. Ascent Group LLC bought a new stake in Grifols in the second quarter worth $141,000. Ballentine Partners LLC increased its position in Grifols by 48.9% in the second quarter. Ballentine Partners LLC now owns 16,179 shares of the biotechnology company's stock worth $146,000 after purchasing an additional 5,311 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Grifols by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company's stock worth $29,948,000 after purchasing an additional 80,507 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Grifols during the first quarter worth $184,000.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.